CONTEXT THERAPEUTICS INC

CNTXNASDAQ

🏆 #3482 by market capEarnings Nov 2US Equity

$0.47▲ $0.01 (+2.98%)

🌙 After hours$0.47▲ 1.65%Regular close · extended-hours price shown

1h—

24h▲ 3.0%

7d▼ 31.5%

14d▼ 24.7%

30d▼ 25.5%

1y▼ 31.9%

🏦Market Cap

$43M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $0.46 – $0.47
52-Week Range: $0.43 – $3.62
Volume: $2.47B
Avg Volume: $2.31B
Shares Outstanding: 91.9M
Next Earnings: Sep 17, 2026

Fundamentals Snapshot

Annual Revenue: $9M
Last Q Revenue: $2M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.48
Dividend Yield: —

Why Investors Own CNTX

✓High-growth profile — revenue up +41.8% YoY with expanding US Equity exposure.
✓Healthy economics — 35% gross margin and 16% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$9M▲ +38.1% YoY

Gross Margin (TTM)

35.1%▲ +1.6% YoY

Operating Income (TTM)

$1M▲ +38.1% YoY

Free Cash Flow (TTM)

$1M▲ +38.1% YoY

About CONTEXT THERAPEUTICS INC

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

🦦